What is FOXO4-DRI?
FOXO4-DRI is a synthetic D-retro-inverso peptide engineered from a segment of the FOXO4 transcription factor. It was designed to penetrate cells and interfere with the interaction between FOXO4 and p53 that can help senescent cells resist apoptosis.
How does FOXO4-DRI work?
In senescent cells, FOXO4 can bind p53 and retain it in the nucleus, supporting survival despite cellular damage. FOXO4-DRI disrupts this interaction, allowing p53-driven apoptotic signaling to proceed. The D-retro-inverso design improves protease resistance compared with a conventional L-amino-acid peptide.
Primary Documented Uses
- Pre-clinical senolytic and aging research
- Study of p53 and FOXO4 signaling in senescent cells
- Experimental models of chemotherapy-induced tissue damage
- Longevity-mechanism research rather than clinical anti-aging therapy
Research Summary
A landmark mouse study reported that FOXO4-DRI reduced senescent-cell burden, restored tissue homeostasis, and improved physical performance in aged and chemotherapy-treated mice. The work remains pre-clinical; human safety, delivery, durability, and cancer-risk implications require careful investigation.
Legal and Regulatory Status
FOXO4-DRI is not FDA-approved and has no established clinical use. It should be treated strictly as a pre-clinical research compound.
Frequently Asked Questions
What is FOXO4-DRI?
FOXO4-DRI is An experimental senolytic peptide designed to disrupt FOXO4-p53 interactions and selectively trigger apoptosis in senescent cells.
How does FOXO4-DRI work?
In senescent cells, FOXO4 can bind p53 and retain it in the nucleus, supporting survival despite cellular damage. FOXO4-DRI disrupts this interaction, allowing p53-driven apoptotic signaling to proceed. The D-retro-inverso design improves protease resistance compared with a conventional L-amino-acid peptide.
What does research say about FOXO4-DRI?
A landmark mouse study reported that FOXO4-DRI reduced senescent-cell burden, restored tissue homeostasis, and improved physical performance in aged and chemotherapy-treated mice. The work remains pre-clinical; human safety, delivery, durability, and cancer-risk implications require careful investigation.
Is FOXO4-DRI FDA-approved or legally available?
FOXO4-DRI is not FDA-approved and has no established clinical use. It should be treated strictly as a pre-clinical research compound.